Advertisement

Topics

Aimmune Therapeutics Inc. Company Profile

07:51 EST 18th December 2018 | BioPortfolio

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.


News Articles [722 Associated News Articles listed on BioPortfolio]

Nestle Health increases stake in Aimmune Therapeutics

Nestlé Health Science has raised its equity stake in biopharmaceutical firm Aimmune Therapeutics to around 19% with an investment of...Read More... The post Nestle Health increases stake in Aimmune T...

Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: R...

Aimmune Therapeutics begins Phase II trial of AR101 and dupilumab

Aimmune Therapeutics has started a Phase II trial of AR101 with adjunctive dupilumab for the treatment of patients with peanut...Read More... The post Aimmune Therapeutics begins Phase II trial of AR1...

Nestlé Health Science increases stake in Aimmune Therapeutics

Aimmune Therapeutics is engaged in the development of advanced treatments for life-threatening food allergies. The latest investment brings Nestlé’s total investment in the drug developer for food ...

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101

Aimmune Therapeutics (Nasdaq:AIMT) a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron...

Nestle erhöht Beteiligung an US-Biopharmaspezialisten Aimmune

Von Colin Kellaher LONDON (Dow Jones)--Nestle erhöht seine Beteiligung an dem US-Biopharmaunternehmen Aimmune Therapeutics. Der Schweizer Konzern investiert weitere 98 Millionen US-Dollar und erhö.....

Aimmune expects FDA decision on peanut allergy therapy in August 2019

Aimmune Therapeutics anticipates an FDA advisory committee meeting for the approval of its lead oral immunotherapy candidate AR101 evaluated to treat peanut allergies,...Read More... The post Aimmu...

Nestle raises stake in food allergy drug developer Aimmune

The health science unit of Nestle SA would pay $98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.

PubMed Articles [454 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1286 Associated Companies listed on BioPortfolio]

Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food a...

Aimmune Therapeutics Inc.

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensit...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Aimmune Therapeutics Inc." on BioPortfolio

We have published hundreds of Aimmune Therapeutics Inc. news stories on BioPortfolio along with dozens of Aimmune Therapeutics Inc. Clinical Trials and PubMed Articles about Aimmune Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aimmune Therapeutics Inc. Companies in our database. You can also find out about relevant Aimmune Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...


Corporate Database Quicklinks



Searches Linking to this Company Record